 |
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
ABBV-927 Therapeutic area:
Cancer
|
 |
AbbVie |
ABT-199/GDC0199 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Chronic Lymphocytic Leukemia / Mieloma Multiple / Leucemia Mieloide Aguda |
3PhIII |
ABT-199/GDC0199 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
AbbVie |
ABT-066 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasis / Psoriatic arthritis / Crohn disease / Ulcerative colitis / Hidrosadenitis Supurativa |
3PhIII |
ABT-066 Therapeutic area:
Autoimmune & Inflammation
|
 |
AbbVie |
ABT450/ABT-267 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT450/ABT-267 Therapeutic area:
Infections
|
 |
AbbVie |
ABBV-323 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
ABBV-323 Therapeutic area:
Autoimmune & Inflammation
|
 |
AbbVie |
Humira (adalimumab) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Hidradenitis Suppurativa / Uveitis / Ulcerative colitis/ Chron Disease / Rheumatoid Arthritis / Psoriasis / Psoriatic Arthritis |
4Reg. |
Humira (adalimumab) Therapeutic area:
Autoimmune & Inflammation
|
 |
AbbVie |
ABT-493 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-493 Therapeutic area:
Infections
|
 |
AbbVie |
ABT-530 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-530 Therapeutic area:
Infections
|
 |
AbbVie |
Veliparib |
Biodrugs/ Drugs |
Cancer |
Breast Cancer / Ovarian cancer |
3PhIII |
Veliparib Therapeutic area:
Cancer
|
 |
AbbVie |
ABBV-647 |
Biodrugs/ Drugs |
Cancer |
Lung cancer |
1PhI |
ABBV-647 Therapeutic area:
Cancer
|
 |
AbbVie |
ABT-555 |
Biodrugs/ Drugs |
Central Nervous System |
Ischemic stroke / Spinal cord injury |
2PhII |
ABT-555 Therapeutic area:
Central Nervous System
|
 |
AbbVie |
ABBV-368 |
Biodrugs/ Drugs |
Cancer |
Head cancer / Neck cancer |
1PhI |
ABBV-368 Therapeutic area:
Cancer
|
 |
AbbVie |
ABBV-399 |
Biodrugs/ Drugs |
Cancer |
NSCLC |
2PhII |
ABBV-399 Therapeutic area:
Cancer
|
 |
AbbVie |
ABT-333 |
Biodrugs/ Drugs |
Infections |
C Hepatitis |
3PhIII |
ABT-333 Therapeutic area:
Infections
|
 |
AbbVie |
ABT-263 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Myelofibrosis |
3PhIII |
ABT-263 Therapeutic area:
Blood and Lymphatic systems
|
 |
AbbVie |
ABT-SLV187 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
4Reg. |
ABT-SLV187 Therapeutic area:
Central Nervous System
|
 |
AbbVie |
ABBV-951 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
3PhIII |
ABBV-951 Therapeutic area:
Central Nervous System
|
 |
AbbVie |
ABBV-181 |
Biodrugs/ Drugs |
Cancer |
Solid tumors / Head cancer / Neck cancer |
1PhI |
ABBV-181 Therapeutic area:
Cancer
|
 |
AbbVie |
ABBV-621 |
Biodrugs/ Drugs |
Cancer |
Colorrectal cancer / Acute Myeloid Leukemia |
1PhI |
ABBV-621 Therapeutic area:
Cancer
|
 |
AbbVie |
ABBV-8E12 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
2PhII |
ABBV-8E12 Therapeutic area:
Central Nervous System
|
 |
AbbVie |
ABT-494 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis / Chron Disease / Ulcerative Colitis/ Atopic Dermatitis / Psoriasic Arthritis / Axial Spondiloarthritis / Giant Cell Artheritis / Juvenil
Idiopatic Arthritis / Lupus / Ankylosing Spondylitis |
3PhIII |
ABT-494 Therapeutic area:
Autoimmune & Inflammation
|
 |
Amgen |
Evolocumab |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems Metabolic / Endocrinology |
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia |
4Reg. |
Evolocumab Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
 |
Amgen |
Denosumab |
Biodrugs/ Drugs |
Cancer |
Giant cell tumour of the bone |
2PhII |
Denosumab Therapeutic area:
Cancer
|
 |
Amgen |
Talimogene laherparepvec |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma |
4Reg. |
Talimogene laherparepvec Therapeutic area:
Cancer
|
 |
Amgen |
Omecantiv mecarbil |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure |
3PhIII |
Omecantiv mecarbil Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Amgen |
Cinacalcet |
Biodrugs/ Drugs |
Autoimmune & Inflammation Kidney and Genitourinary system |
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT |
4Reg. |
Cinacalcet Therapeutic area:
Autoimmune & Inflammation / Kidney and Genitourinary system
|
 |
Amgen |
Romiplostim |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) |
4Reg. |
Romiplostim Therapeutic area:
Blood and Lymphatic systems
|
 |
Amgen |
Etelcalcetide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Secondary Hyperparathyroidism |
4Reg. |
Etelcalcetide Therapeutic area:
Metabolic / Endocrinology
|
 |
Amgen |
Romosozumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders Women´s health |
Postmenopausal osteoporosis |
3PhIII |
Romosozumab Therapeutic area:
Musculoskeletal Disorders / Women´s health
|
 |
Amgen |
Denosumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer |
4Reg. |
Denosumab Therapeutic area:
Musculoskeletal Disorders
|
 |
Amgen |
Blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Acute lymphoblastic leukaemia |
4Reg. |
Blinatumomab Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Breast: Metastatic
Non-small cell lung: Advanced
Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure |
2PhII |
CC 486 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
CC-90009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
CC-90009 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles) |
Biodrugs/ Drugs |
Cancer |
Solid tumors , breast metastatic.
Nonsmall cell lung advanded (First line)
Pancratic metastatic ( First line)
gastric metastatic ( Japan) |
4Reg. |
Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles) Therapeutic area:
Cancer
|
 |
Celgene |
LSD1 Inhibitor: CC-90011 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
LSD1 Inhibitor: CC-90011 Therapeutic area:
Cancer
|
 |
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Peripheral T-cell lymphoma:First-line |
3PhIII |
ISTODAX® (romidepsin) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Avadomide (CC-122) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma. Diffuse large B-cell lymphoma |
1PhI |
Avadomide (CC-122) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
SOTATERCEPT (ACE-011) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Chronic kidney disease |
2PhII |
SOTATERCEPT (ACE-011) Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
OTEZLA® (Apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Ankylosing spondylitis
Behcets disease |
4Reg. |
OTEZLA® (Apremilast) Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Celgene |
CC-220 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Systemic lupus erythematosus |
2PhII |
CC-220 Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
ISTODAX ( romidepsin) for injection |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma. Cutaneous T-cell Lymphoma (US). |
4Reg. |
ISTODAX ( romidepsin) for injection Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
OTEZLA® (apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
OTEZLA® (apremilast) Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC 486 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Pomalyst ( imnovid ( pomalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
4Reg. |
Pomalyst ( imnovid ( pomalidomide) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
CC-220 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
CC-220 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
ABRAXANE® |
Biodrugs/ Drugs |
Cancer |
Pancreatic:Adjuvant |
3PhIII |
ABRAXANE® Therapeutic area:
Cancer
|
 |
Celgene |
CC-90006 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Autoinmune disorders:psoriasis |
1PhI |
CC-90006 Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Peripheral T-cell lymphoma: relapsed/refractory (Japan) |
2PhII |
ISTODAX® (romidepsin) Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
REVLIMID ( lenalidomida) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myelome (MM): Relapsed/refractory
Newly diagnosed
Maintenance
Myelodyplastic syndromes (MDS) deletion 5q.
lymphoma: mantle cell lymphoma , relapsed/ refratory. |
4Reg. |
REVLIMID ( lenalidomida) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Thalomid / thalidomide celgene (Thalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
4Reg. |
Thalomid / thalidomide celgene (Thalidomide) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
CC-90001 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Fibrosis |
2PhII |
CC-90001 Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
VIDAZA® (azacitidine for injection) |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Acute myeloid laeukemia (AML) (>30% blasts) |
4Reg. |
VIDAZA® (azacitidine for injection) Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
AG-881 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Acute Myeloid Leukemia (AML)
Glioma |
1PhI |
AG-881 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
Morgensen (GED-0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation Digestive System |
Ulcerative colitis |
2PhII |
Morgensen (GED-0301) Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Celgene |
REVLIMID ( lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
lymphoma: Adult T-cell leukemia- lymphoma (Japan) |
3PhIII |
REVLIMID ( lenalidomide) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
BCMA CAR T (JCARH125) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) |
1PhI |
BCMA CAR T (JCARH125) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
PD-L1 Inhibitor:durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Multiple Myeloma (MM)
Chronic Lymphocytic Leukemia (CLL)
No-Hodgkin Lymphoma (NHL) |
1PhI |
PD-L1 Inhibitor:durvalumab Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
CD19 CAR-T (JCAR017) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Aggressive large B-cell lymphoma: Relapsed/refractory |
1PhI |
CD19 CAR-T (JCAR017) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
AG-221 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
3PhIII |
AG-221 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
OTEZLA (apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Psoriatic arthritis (PsA) Psoriasis |
4Reg. |
OTEZLA (apremilast) Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Celgene |
CC-92480 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
1PhI |
CC-92480 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Mongersen (GED 0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation Digestive System |
Crohn's disease |
3PhIII |
Mongersen (GED 0301) Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Celgene |
PDA-002 |
Biodrugs/ Drugs |
Others |
Diabetic foot ulcers
Diabetic peripheral neuropathy |
2PhII |
PDA-002 Therapeutic area:
Others
|
 |
Celgene |
BCMA CAR-T (bb2121) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) |
1PhI |
BCMA CAR-T (bb2121) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
AG-120 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
AG-120 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
IDHIFA (enasidenib) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Myelodyplastic Syndromes (MDS) RElapsed/refractory IDH2 mutation (US) |
4Reg. |
IDHIFA (enasidenib) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
PNK-007 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM) |
1PhI |
PNK-007 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
CC-93269 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
1PhI |
CC-93269 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Luspatercept (ACE-536) |
Biodrugs/ Drugs |
Cancer |
Myelofibrosis: MF Anemia |
2PhII |
Luspatercept (ACE-536) Therapeutic area:
Cancer
|
 |
Celgene |
Citarinostat (ACY-241) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
Citarinostat (ACY-241) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
CAR-T (JCAR15) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
ALL( Accute Lymphoblastic Leukemia) |
2PhII |
CAR-T (JCAR15) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
IDHIFA (enasidenib) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
myelody syndromes (MDS(Newly diagnosed AML with an IDH2 mutation |
1PhI |
IDHIFA (enasidenib) Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
RPC4046 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Eosinophilic esophagitis |
2PhII |
RPC4046 Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
Fedratinib |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Myelofibrosis: MF anemia |
3PhIII |
Fedratinib Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
Luspatercept (ACE-536) |
Biodrugs/ Drugs |
Blood and Lymphatic systems Others |
Myelodisplastic Syndromes (MDS)
Beta-thalassemia |
3PhIII |
Luspatercept (ACE-536) Therapeutic area:
Blood and Lymphatic systems / Others
|
 |
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC-486 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
Marizomib |
Biodrugs/ Drugs |
Cancer |
solid tumors. Glioblastoma |
2PhII |
Marizomib Therapeutic area:
Cancer
|
 |
Celgene |
PPM Pleiotropic Pathway Modifier: CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Hepatocellular carcinoma |
2PhII |
PPM Pleiotropic Pathway Modifier: CC-122 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Breast. metastatic nonsmall cell lung: advanced myelodysplastic syndromes ( MDS) : post hypomethylating agent (HMA) failure. |
2PhII |
CC-486 Therapeutic area:
Blood and Lymphatic systems
|
 |
Celgene |
REVLIMID® (lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Diffuse large B-cell lymphoma (ABC subtype): First line
Indolent lymphoma: relapsed/refractory
Follicular lymphoma: first line |
3PhIII |
REVLIMID® (lenalidomide) Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
PD-L1 Inhibitor: durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML) |
2PhII |
PD-L1 Inhibitor: durvalumab Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
Tislelizumab |
Biodrugs/ Drugs |
Cancer |
solid tumors. non-small cell lung cancer. Hepatocellular carcinoma. Esophageal squamous cell carcinoma |
3PhIII |
Tislelizumab Therapeutic area:
Cancer
|
 |
Celgene |
BET inhibitor: CC-90010 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
lymphoma. Non-hodgkin lymphoma (NHL) |
1PhI |
BET inhibitor: CC-90010 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis
Relapsing multiple sclerosis |
3PhIII |
Ozanimod Therapeutic area:
Autoimmune & Inflammation
|
 |
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Myelodysplastic Syndromes (MDS): lower-risk
Post-induction AML maintenance |
3PhIII |
CC-486 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
Anti-CD47 Antibody: CC-90002 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Solid Tumors
lymphoma: non-hogdkin lymphoma (NHL) |
1PhI |
Anti-CD47 Antibody: CC-90002 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Lymphoma: Diffuse large B-Cell & Indolent lymphoma: relapsed/refractory
Hepatocellular carcinoma
Multiple Myeloma
Chronic Lymphocytic Leukemia (CLL) |
1PhI |
CC-122 Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Celgene |
BET inhibitor: CC-90010 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
BET inhibitor: CC-90010 Therapeutic area:
Cancer
|
 |
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn`s disease |
3PhIII |
Ozanimod Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Momelotinib |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
2PhII |
Momelotinib Therapeutic area:
Cancer
|
 |
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn's Disease and Ulcerative colitis |
2PhII |
Filgotinib (JAK1 inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir |
Biodrugs/ Drugs |
Infections |
HIV/AIDS - PreExposure Profilaxis |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir Therapeutic area:
Infections
|
 |
Gilead Sciences |
Entosplenitib (Syk inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Hematological malignances |
2PhII |
Entosplenitib (Syk inhibitor) Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
Tirabrutinib (BTK inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
B-cell malignancies |
2PhII |
Tirabrutinib (BTK inhibitor) Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
Presatovir ( Fusion inhibitor) |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Respiratory Syncytial Virus |
2PhII |
Presatovir ( Fusion inhibitor) Therapeutic area:
Respiratory and Pulmonary system
|
 |
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Digestive System |
Nonalcoholic steatohaepatitis |
2PhII |
GS-4997 (ASK-1 inhibitor) Therapeutic area:
Digestive System
|
 |
Gilead Sciences |
Alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Alafenamide STR Therapeutic area:
Infections
|
 |
Gilead Sciences |
GS-9722 (bNab) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-9722 (bNab) Therapeutic area:
Infections
|
 |
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Digestive System |
Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis |
2PhII |
Simtuzumab Therapeutic area:
Digestive System
|
 |
Gilead Sciences |
GS-9876 ( Syk Inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Sjogren's Syndrome |
2PhII |
GS-9876 ( Syk Inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC Therapeutic area:
Infections
|
 |
Gilead Sciences |
Axicabtagene ciloleucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
DLBCL ,PMBCL & TFL |
3PhIII |
Axicabtagene ciloleucel Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
GS-9688 (TLR-8 Agonist) |
Biodrugs/ Drugs |
Infections |
HBV |
1PhI |
GS-9688 (TLR-8 Agonist) Therapeutic area:
Infections
|
 |
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiopathic pulmonary fibrosis |
2PhII |
Simtuzumab Therapeutic area:
Respiratory and Pulmonary system
|
 |
Gilead Sciences |
GS-9876 (Syk inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Lupus |
2PhII |
GS-9876 (Syk inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR Therapeutic area:
Infections
|
 |
Gilead Sciences |
Axicabtagene colileucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Indolent NHL |
2PhII |
Axicabtagene colileucel Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
3PhIII |
Selonsertib ( ASK-1 Inhibitor) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
GS-4875 (TPL2 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Inflammatory Bowel |
1PhI |
GS-4875 (TPL2 inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Vestalimod ( GS-9620, TRL-7 agonist) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
Vestalimod ( GS-9620, TRL-7 agonist) Therapeutic area:
Infections
|
 |
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MCL |
2PhII |
KTE-C19 Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Alcoholic Hepatitis |
2PhII |
Selonsertib ( ASK-1 Inhibitor) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
Remdesivir ( Gs-5734, Nuc. Inhibitor) |
Biodrugs/ Drugs |
Infections |
Ebola Virus infection |
2PhII |
Remdesivir ( Gs-5734, Nuc. Inhibitor) Therapeutic area:
Infections
|
 |
Gilead Sciences |
GS-62'7 (capsid inhibitor) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-62'7 (capsid inhibitor) Therapeutic area:
Infections
|
 |
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult ALL |
1PhI |
KTE-C19 Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
GS-5806 (fusion inhibitor) |
Biodrugs/ Drugs |
Infections Respiratory and Pulmonary system |
Respiratory syncytial virus |
2PhII |
GS-5806 (fusion inhibitor) Therapeutic area:
Infections / Respiratory and Pulmonary system
|
 |
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-9674 (FXR Agonist) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
GS-9131 (NRTI) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
GS-9131 (NRTI) Therapeutic area:
Infections
|
 |
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Pedriatic ALL |
1PhI |
KTE-C19 Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
GS-6615 (late sodium current inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Ventricular tachycardia / Ventricular fibrillation |
2PhII |
GS-6615 (late sodium current inhibitor) Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Bilinary Cirrhosis |
2PhII |
GS-9674 (FXR Agonist) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
KITE-585 ( anti-BCMA) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MM |
1PhI |
KITE-585 ( anti-BCMA) Therapeutic area:
Blood and Lymphatic systems
|
 |
Gilead Sciences |
ERK Inhibitor |
Biodrugs/ Drugs |
Cancer |
Cancer |
1PhI |
ERK Inhibitor Therapeutic area:
Cancer
|
 |
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Pulmonary arterial hypertension |
2PhII |
GS-4997 (ASK-1 inhibitor) Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Sclerosing Cholangit |
2PhII |
GS-9674 (FXR Agonist) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
KITE-718 ( MAGE A3/A6) |
Biodrugs/ Drugs |
Cancer |
Solid tumor. |
1PhI |
KITE-718 ( MAGE A3/A6) Therapeutic area:
Cancer
|
 |
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
GS-5745 (MMP9 mAb inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
GS-0976 ( ACC Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-0976 ( ACC Inhibitor) Therapeutic area:
Metabolic / Endocrinology
|
 |
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Gastric cancer |
3PhIII |
Andecaliximab (MMP9 mAb inhibitor) Therapeutic area:
Cancer
|
 |
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
GS-5745 (MMP9 mAb inhibitor) Therapeutic area:
Cancer
|
 |
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid Arthritis |
3PhIII |
Filgotinib (JAK1 inhibitor) Therapeutic area:
Autoimmune & Inflammation
|
 |
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
Andecaliximab (MMP9 mAb inhibitor) Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Cholangiocarcinoma |
2PhII |
Pemigatinib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
8p11 MPN |
2PhII |
Pemigatinib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Follicular lymphoma |
2PhII |
Parsaclisib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Marginal zone lymphoma |
2PhII |
Parsaclisib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Chronic graft-versus-host disease |
3PhIII |
Itacitinib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Mantle cell lymphoma |
2PhII |
Parsaclisib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) |
2PhII |
Itacitinib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
MSI-H endometrial cancer (In collaboration with MacroGenics) |
1PhI |
INCMGA0012 Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Bladder cancer |
2PhII |
Pemigatinib Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Merkel cell carcinoma (In collaboration with MacroGenics) |
2PhII |
INCMGA0012 Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Anal cancer (In collaboration with MacroGenics) |
2PhII |
INCMGA0012 Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCB01158 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Co-development with Calithera) |
2PhII |
INCB01158 Therapeutic area:
Cancer
|
 |
Incyte Biosciences Iberia |
INCAGN1876 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Discovery alliance with Agenus) |
2PhII |
INCAGN1876 Therapeutic area:
Cancer
|
 |
Merck KGaA |
Bintrafusp alfa |
Biodrugs/ Drugs |
Cancer |
TGFbeta trap/anti-PD-L1. Non-small cell lung cancer 1L / 1L/2L / Locally advanced non-small cell lung cancer / Biliary tract cancer 1L / Biliary tract cancer 2L / Cervical cancer 2L |
2PhII |
Bintrafusp alfa Therapeutic area:
Cancer
|
 |
Merck KGaA |
Peposertib (M3814) |
Biodrugs/ Drugs |
Cancer |
DNA-PK inhibitor. Rectal cancer |
2PhII |
Peposertib (M3814) Therapeutic area:
Cancer
|
 |
Merck KGaA |
M3258 |
Biodrugs/ Drugs |
Cancer |
LMP7 inhibitor. Multiple myeloma |
1PhI |
M3258 Therapeutic area:
Cancer
|
 |
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Non-small cell lung cancer 1L |
3PhIII |
Avelumab Therapeutic area:
Cancer
|
 |
Merck KGaA |
M1774 |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
M1774 Therapeutic area:
Cancer
|
 |
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Urothelial cancer 1L-M |
4Reg. |
Avelumab Therapeutic area:
Cancer
|
 |
Merck KGaA |
M5049 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
TLR7/8 antagonist. Immunology |
1PhI |
M5049 Therapeutic area:
Autoimmune & Inflammation
|
 |
Merck KGaA |
Abituzumab |
Biodrugs/ Drugs |
Cancer |
pan-αν integrin inhibiting mAb. Colorectal Cancer 1L |
2PhII |
Abituzumab Therapeutic area:
Cancer
|
 |
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
anti-PD-L1 mAb. Several types of cancer (Merkel cell cancer 1L / urothelial cancer / solid tumors and non-small cell lung cancer 1L in combination with talazoparib, axitinib, ALK inhibitors, cetuximab, or chemotherapy). |
2PhII |
Avelumab Therapeutic area:
Cancer
|
 |
Merck KGaA |
M6495 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
anti-ADAMTS-5 nanobody. Osteoarthritis |
1PhI |
M6495 Therapeutic area:
Autoimmune & Inflammation
|
 |
Merck KGaA |
Atacicept |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Anti-BlyS/APRIL fusion protein. Systemic lupus erythematosus / IgA nephropathy |
2PhII |
Atacicept Therapeutic area:
Autoimmune & Inflammation
|
 |
Merck KGaA |
Peposertib (M3814) |
Biodrugs/ Drugs |
Cancer |
DNA-PK inhibitor. Solid tumors in combination with avelumab |
1PhI |
Peposertib (M3814) Therapeutic area:
Cancer
|
 |
Merck KGaA |
Sprifermin |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
fibroblast growth factor 18. Osteoarthritis |
2PhII |
Sprifermin Therapeutic area:
Autoimmune & Inflammation
|
 |
Merck KGaA |
Berzosertib (M6620) |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
Berzosertib (M6620) Therapeutic area:
Cancer
|
 |
Merck KGaA |
M4344 |
Biodrugs/ Drugs |
Cancer |
ATR inhibitor. Solid tumors |
1PhI |
M4344 Therapeutic area:
Cancer
|
 |
Merck KGaA |
M1095 (ALX-0761) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
anti-IL-17 A/F nanobody. Psoriasis |
2PhII |
M1095 (ALX-0761) Therapeutic area:
Autoimmune & Inflammation
|
 |
Merck KGaA |
M8891 |
Biodrugs/ Drugs |
Cancer |
MetAP2 inhibitor. Solid tumors |
1PhI |
M8891 Therapeutic area:
Cancer
|
 |
Merck KGaA |
M5717 |
Biodrugs/ Drugs |
Infections |
PeEF2 inhibitor. Malaria |
1PhI |
M5717 Therapeutic area:
Infections
|
 |
Merck KGaA |
Tepotinib |
Biodrugs/ Drugs |
Cancer |
MET kinase inhibitor. Non-small cell lung cancer |
2PhII |
Tepotinib Therapeutic area:
Cancer
|
 |
Merck KGaA |
Tepotinib |
Biodrugs/ Drugs |
Cancer |
MET kinase inhibitor. Non-small cell lung cancer, METex14 skipping |
4Reg. |
Tepotinib Therapeutic area:
Cancer
|
 |
Merck KGaA |
Bintrafusp alfa |
Biodrugs/ Drugs |
Cancer |
TGFbeta trap/anti-PD-L1. Solid tumors |
1PhI |
Bintrafusp alfa Therapeutic area:
Cancer
|
 |
Merck KGaA |
Evobrutinib |
Biodrugs/ Drugs |
Central Nervous System |
BTK inhibitor. Multiple sclerosis |
3PhIII |
Evobrutinib Therapeutic area:
Central Nervous System
|
 |
Merck KGaA |
M9241 (NHS-IL12) |
Biodrugs/ Drugs |
Cancer |
Cancer immunotherapy. Solid tumors in combination with avelumab |
1PhI |
M9241 (NHS-IL12) Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Perioperative Pembrolizumab for Cis-Ineligible MIBC |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Triple-Negative Breast Cancer (mTNBC) |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Mavezelimab/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
Mavezelimab/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo in Surgically Resected or Ablated HCC Patients |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Vericiguat |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure with reduced ejection Fraction |
3PhIII |
Vericiguat Therapeutic area:
Cardiovascular and circulatory systems
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma |
3PhIII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in children and young adults with newly diagnosed Classical Hodgkin Lymphoma |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Islatravir |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Islatravir Therapeutic area:
Infections
|
 |
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric subjects with nosocomial pneumonia (HABP/VABP) |
1PhI |
ZERBAXA Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line study of pembrolizumab +/- epacadostat in NSCLC |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) |
2PhII |
Prevymis (Letermovir) Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor |
2PhII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Progressive or recurrent Intermediate or High risk, Non-muscle invasive Urothelial Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II (biomarker directed) Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
RIG-I |
Biodrugs/ Drugs |
Cancer |
Advanced/Metastatic or Recurrent Solid Tumors |
1PhI |
RIG-I Therapeutic area:
Cancer
|
 |
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
V937 as Monotherapy or in Combination with Pembrolizumab in Participants With BCG-Unresponsive High-Risk NMIBC |
2PhII |
CAVATAK/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC) |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Inactivated VZV Vaccine |
Vaccines |
Blood and Lymphatic systems Cancer |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in Participants with solid tumors Previously Treated |
2PhII |
Olaparib Therapeutic area:
Cancer
|
 |
MSD |
15-valent Pneumococcal Conjugate Vaccine |
Vaccines |
Infections |
Pneumoccoco in healthy adults 50 years of age or older |
3PhIII |
15-valent Pneumococcal Conjugate Vaccine Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Gardasil 9 |
Vaccines |
Infections |
VPH in preadolescents and adolescents |
3PhIII |
Gardasil 9 Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Gefapixant |
Biodrugs/ Drugs |
Women´s health |
Moderate to Severe Endometriosis-related Pain |
2PhII |
Gefapixant Therapeutic area:
Women´s health
|
 |
MSD |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 |
Biodrugs/ Drugs |
Cancer |
Umbrella trial in First Line Metastatic non-squamous and squamous Non-small Cell Lung Cancer Subjects with pembrolizumab and MK-7684 or MK-4830 and in previously treated PD-1/PDL-1 patients receiving pembrolizumab and MK-5890 or MK-4830 |
2PhII |
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Compared with Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III No |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of ITu V937 in Combination with Pembrolizumab selected solid tumors |
2PhII |
CAVATAK/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
High-risk Non Muscle Invassive Bladder Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Sugammadex/BRIDION |
Biodrugs/ Drugs |
Others |
Anesthesiology. Reversal of Neuromuscular Blockade in Pediatric Population |
4Reg. |
Sugammadex/BRIDION Therapeutic area:
Others
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
10 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
20 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
HIF-2α inhibitor |
Biodrugs/ Drugs |
Cancer |
MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies |
3PhIII |
HIF-2α inhibitor Therapeutic area:
Cancer
|
 |
MSD |
V160 |
Vaccines |
Infections |
Prevention CMVin women 16-35 dosis vx 3 dosis |
2PhII |
V160 Therapeutic area:
Infections
|
 |
MSD |
Pneumococcal vaccine polyvalent |
Vaccines |
Infections |
Paedriatric Prevention of pneumococal infection with V114 |
3PhIII |
Pneumococcal vaccine polyvalent Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
MK4830 |
Biodrugs/ Drugs |
Cancer |
MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors |
1PhI |
MK4830 Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
first Line Study of Pembrolizumab +/- Ipilimumab in NSCLC |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC |
3PhIII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
3PhIII |
Lenvatinib/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Lenvatinib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor |
2PhII |
Lenvatinib/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
RECARBRIO (mk7655A) |
Biodrugs/ Drugs |
Infections |
Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection |
3PhIII |
RECARBRIO (mk7655A) Therapeutic area:
Infections
|
 |
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients |
1PhI |
ZERBAXA Therapeutic area:
Respiratory and Pulmonary system
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR |
1PhI |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Gardasil 9 |
Vaccines |
Infections |
9vHPV vaccine in adult males 20 to 45 years of age |
3PhIII |
Gardasil 9 Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors |
1PhI |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
MK1454/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma |
2PhII |
MK1454/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Olaparib/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated |
2PhII |
Olaparib/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/TACE |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma |
3PhIII |
Pembrolizumab/TACE Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib versus docetaxel for metastatic Non-Small Cell Lung Cancer after platinum doublet chemotherapy and immunotherapy |
3PhIII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Trastuzumab + Chemotherapy with/without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III extension study for participants with advanced tumors in pembrolizumab trials |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors |
2PhII |
Pembrolizumab/Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
RSV Vaccine |
Biodrugs/ Drugs |
Infections |
VRS prevention in preterm infants |
2PhII |
RSV Vaccine Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-genera |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
BET Inhibitor |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
BET Inhibitor Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Lenvatinib |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lung cancer |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
ZINPLAVA |
Biodrugs/ Drugs |
Infections |
In Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) |
3PhIII |
ZINPLAVA Therapeutic area:
Infections
|
 |
MSD |
Golimumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Non-radiographic axial Spondyloarthritis |
4Reg. |
Golimumab Therapeutic area:
Autoimmune & Inflammation
|
 |
MSD |
Anti CTLA-4/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase) |
2PhII |
Anti CTLA-4/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
MK-5890/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Selected Advanced Solid Tumors |
1PhI |
MK-5890/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Epacadostat |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia |
1PhI |
Posaconazole Therapeutic area:
Infections
|
 |
MSD |
Gefapixant |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Chronic cough |
3PhIII |
Gefapixant Therapeutic area:
Respiratory and Pulmonary system
|
 |
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lubng cancer |
3PhIII |
Pembrolizumab/Olaparib Therapeutic area:
Cancer
|
 |
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib vs Olaparib + Bevacizumab vs 5FU + Bevacizumab
in metastasic colorectal cancer |
3PhIII |
Olaparib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab vs chemotherapy in patients with advanced melanoma |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies |
2PhII |
Lenvatinib Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced/Unresectable or Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems Metabolic / Endocrinology |
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease |
3PhIII |
Anacetrapib Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) and Relapsed or Refractory Richter Syndrome |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients |
3PhIII |
Prevymis (Letermovir) Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with recurrent ovarian cancer |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
CAVATAK/Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
V937 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma |
2PhII |
CAVATAK/Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. |
3PhIII |
Posaconazole Therapeutic area:
Infections
|
 |
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of CMV disease in D+/R- kidney transplant recipients |
3PhIII |
Prevymis (Letermovir) Therapeutic area:
Infections
|
 |
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric Subjects with Complicated Intra-Abdominal Infection |
2PhII |
ZERBAXA Therapeutic area:
Infections
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Neoadjuvant treatment Platinum Doublet Chemotherapy +/-Pembrolizumab followed by Surgery |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer |
3PhIII |
Pembrolizumab Therapeutic area:
Cancer
|
 |
Novo Nordisk Pharma |
Somapacitan(Long-acting growth hormone) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Growth hormone deficiency |
3PhIII |
Somapacitan(Long-acting growth hormone) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Insulin LA287 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Insulin LA287 Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Monoclonal antibody anti Il-21 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
2PhII |
Monoclonal antibody anti Il-21 Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Concizumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A and B |
2PhII |
Concizumab Therapeutic area:
Blood and Lymphatic systems
|
 |
Novo Nordisk Pharma |
Semaglutide NASH |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Non-alcoholic steatohepatitis |
2PhII |
Semaglutide NASH Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Oral semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Oral semaglutide Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Prandial Bioedge |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Prandial Bioedge Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Semaglutide obesidad |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
3PhIII |
Semaglutide obesidad Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Semaglutide Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
AM833 (amilyn analogue) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
AM833 (amilyn analogue) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Liraglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 in paediatric population |
3PhIII |
Liraglutide Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
G530L (glucagon analogue/liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
G530L (glucagon analogue/liraglutide) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Nonacog beta pegol |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia B |
4Reg. |
Nonacog beta pegol Therapeutic area:
Blood and Lymphatic systems
|
 |
Novo Nordisk Pharma |
PYY1562 (analogue peptid YY) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
PYY1562 (analogue peptid YY) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
N8-GP (glycopegylated recombinant FVIII) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
N8-GP (glycopegylated recombinant FVIII) Therapeutic area:
Blood and Lymphatic systems
|
 |
Novo Nordisk Pharma |
IDegAsp (combination insulin degludec + insulin aspart) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 and type 1 |
4Reg. |
IDegAsp (combination insulin degludec + insulin aspart) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Faster-acting insulin aspart (FIAsp) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and type 2 |
4Reg. |
Faster-acting insulin aspart (FIAsp) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
IDegLira (combination insulin degludec + liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
4Reg. |
IDegLira (combination insulin degludec + liraglutide) Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Liraglutide 3mg |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
4Reg. |
Liraglutide 3mg Therapeutic area:
Metabolic / Endocrinology
|
 |
Novo Nordisk Pharma |
Turoctocog alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
4Reg. |
Turoctocog alfa Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
KADCYLA Therapeutic area:
Cancer
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
TIRAGOLUMAB Therapeutic area:
Cancer
|
 |
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
KADCYLA Therapeutic area:
Cancer
|
 |
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Musculoskeletal Disorders |
3PhIII |
OCRELIZUMAB Therapeutic area:
Central Nervous System
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthristis ( juvenile) |
4Reg. |
ACTEMRA Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
ZELBORAF Therapeutic area:
Cancer
|
 |
Roche |
PLGF MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PLGF MAB Therapeutic area:
Cancer
|
 |
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
PICTILISIB Therapeutic area:
Cancer
|
 |
Roche |
BET |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
BET Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
MABTHERA |
Biodrugs/ Drugs |
Autoimmune & Inflammation Dermatology |
Pemphigus |
3PhIII |
MABTHERA Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
 |
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
COBIMETINIB Therapeutic area:
Cancer
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site. |
4Reg. |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
3PhIII |
GAZYVA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
3PhIII |
ONARTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
PDL1 MAB Therapeutic area:
Cancer
|
 |
Roche |
FAP 4-1BBL iMAb |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
FAP 4-1BBL iMAb Therapeutic area:
Cancer
|
 |
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
PERJETA Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
4Reg. |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
HERCEPTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
2PhII |
HERCEPTIN Therapeutic area:
Cancer
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and unspecified parts of biliary tract |
3PhIII |
GAZYVA Therapeutic area:
Cancer
|
 |
Roche |
MabThera |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Follicular ( nodular) non-hodgkin's lymphoma |
3PhIII |
MabThera Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
2PhII |
TIRAGOLUMAB Therapeutic area:
Cancer
|
 |
Roche |
LEBRIKIZUMAB |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Other diseases of upper respiratory tract |
2PhII |
LEBRIKIZUMAB Therapeutic area:
Respiratory and Pulmonary system
|
 |
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
ALEGLITAZAR Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic sclerosis |
3PhIII |
ACTEMRA Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Lymphoid leukaemia |
3PhIII |
GAZYVA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
4Reg. |
OX40 Therapeutic area:
Cancer
|
 |
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
PICTILISIB Therapeutic area:
Cancer
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
MABTHERA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Other malignant neoplasms of skin |
1PhI |
DULIGOTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
cadherin-11 MAb |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis |
2PhII |
cadherin-11 MAb Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
TASELISIB Therapeutic area:
Cancer
|
 |
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
FAP IL2V FP Therapeutic area:
Cancer
|
 |
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
PERJETA Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
2PhII |
LIFASTUZUMAB VEDOTIN Therapeutic area:
Cancer
|
 |
Roche |
GPC3 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of liver |
2PhII |
GPC3 MAB Therapeutic area:
Cancer
|
 |
Roche |
Myostatin |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Duchenne muscular dystrophy |
3PhIII |
Myostatin Therapeutic area:
Musculoskeletal Disorders
|
 |
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
3PhIII |
DALCETRAPIB Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Roche |
VEFG- ANG2 Bsb |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
3PhIII |
VEFG- ANG2 Bsb Therapeutic area:
Ophthalmology and optometry
|
 |
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
APITOLISIB Therapeutic area:
Cancer
|
 |
Roche |
MERICITABINE |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
MERICITABINE Therapeutic area:
Infections
|
 |
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
ALEGLITAZAR Therapeutic area:
Metabolic / Endocrinology
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Malignant neoplasms of lymphoid haematopoietic + |
3PhIII |
GAZYVA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
3PhIII |
POLATUZUMAB VEDOTIN Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
SEMBRAGILINE |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
SEMBRAGILINE Therapeutic area:
Central Nervous System
|
 |
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
APITOLISIB Therapeutic area:
Cancer
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
3PhIII |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Lymphoid leukaemia |
3PhIII |
MABTHERA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
EM RA PRED DEV |
Biodrugs/ Drugs |
Autoimmune & Inflammation Digestive System |
Crohn's disease |
1PhI |
EM RA PRED DEV Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
HPV16 TI |
Biodrugs/ Drugs |
Infections |
Viral agents as cause of diseases classified to other |
2PhII |
HPV16 TI Therapeutic area:
Infections
|
 |
Roche |
MIRCERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Chronic renal failure anemia |
2PhII |
MIRCERA Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
VANUCIZUMAB Therapeutic area:
Cancer
|
 |
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
non-Small cell lung cancer |
2PhII |
FAP IL2V FP Therapeutic area:
Cancer
|
 |
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
PERJETA Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
NEORECORMON |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Anaemia in neoplastic disease |
2PhII |
NEORECORMON Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
3PhIII |
COBIMETINIB Therapeutic area:
Cancer
|
 |
Roche |
Asyn MAb |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson's disease |
2PhII |
Asyn MAb Therapeutic area:
Central Nervous System
|
 |
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis |
4Reg. |
OCREVUS Therapeutic area:
Central Nervous System
|
 |
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
DALCETRAPIB Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
 |
Roche |
XOLAIR |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
other diseases of upper respiratory tract |
3PhIII |
XOLAIR Therapeutic area:
Respiratory and Pulmonary system
|
 |
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
APITOLISIB Therapeutic area:
Cancer
|
 |
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
2PhII |
ONARTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
KADCYLA Therapeutic area:
Cancer
|
 |
Roche |
selicrelumab |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
selicrelumab Therapeutic area:
Cancer
|
 |
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
VANUCIZUMAB Therapeutic area:
Cancer
|
 |
Roche |
BASIMGLURANT |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Fragile X Syndrome |
2PhII |
BASIMGLURANT Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Other + unspecif. types of non-Hodgkin's lymphoma |
3PhIII |
MABTHERA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation Digestive System |
Crohn's disease |
3PhIII |
ETROLIZUMAB Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Malignant neoplams of lymphoid haematopoietic |
1PhI |
CD20 CD3 TDB Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
IGF1R MAB Therapeutic area:
Cancer
|
 |
Roche |
mPI3K alpha inh |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
mPI3K alpha inh Therapeutic area:
Cancer
|
 |
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
1PhI |
VENETOCLAX Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
GAZYVA Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
TASELISIB Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
PATECLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
PATECLIZUMAB Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Irritable bowel syndrome |
3PhIII |
ETROLIZUMAB Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
breast cancer |
4Reg. |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Primary progresive multiple sclerosis |
3PhIII |
OCREVUS Therapeutic area:
Central Nervous System
|
 |
Roche |
HCV POL INH PRO |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
HCV POL INH PRO Therapeutic area:
Infections
|
 |
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECENSA Therapeutic area:
Cancer
|
 |
Roche |
BRAF KIN INH (2) |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
BRAF KIN INH (2) Therapeutic area:
Cancer
|
 |
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
ONARTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
KADCYLA Therapeutic area:
Cancer
|
 |
Roche |
SMN2 splicer (2) |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Spinal muscular atrophy and related syndromes |
3PhIII |
SMN2 splicer (2) Therapeutic area:
Musculoskeletal Disorders
|
 |
Roche |
ALPHA7 NIC AGO |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ALPHA7 NIC AGO Therapeutic area:
Central Nervous System
|
 |
Roche |
CMV ANTI |
Biodrugs/ Drugs |
Infections |
Cytomegaloviral disease |
2PhII |
CMV ANTI Therapeutic area:
Infections
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
PEGASYS |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
PEGASYS Therapeutic area:
Infections
|
 |
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
1PhI |
IMGATUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
2PhII |
POLATUZUMAB VEDOTIN Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
IGF1R MAB Therapeutic area:
Cancer
|
 |
Roche |
SERD (2) |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
SERD (2) Therapeutic area:
Cancer
|
 |
Roche |
CD40 IMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CD40 IMAB Therapeutic area:
Cancer
|
 |
Roche |
HEMLIBRA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
HEMLIBRA Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Lymphoid leukaemia |
3PhIII |
VENETOCLAX Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
other unspecificed types of non-hodgkin's lymphoma |
2PhII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
GANTENERUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
GANTENERUMAB Therapeutic area:
Central Nervous System
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Cervical cancer |
2PhII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Relapsing-remitting multiple sclerosis |
3PhIII |
OCREVUS Therapeutic area:
Central Nervous System
|
 |
Roche |
LAMPALIZUMAB |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
4Reg. |
LAMPALIZUMAB Therapeutic area:
Ophthalmology and optometry
|
 |
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
4Reg. |
ALECENSA Therapeutic area:
Cancer
|
 |
Roche |
CEA IL2V |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA IL2V Therapeutic area:
Cancer
|
 |
Roche |
PARSATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
PARSATUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Rheumatoid arthritis |
3PhIII |
OCRELIZUMAB Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Roche |
Tau Mab (37D3) |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
Tau Mab (37D3) Therapeutic area:
Central Nervous System
|
 |
Roche |
ANTI-INFLUENZA A |
Biodrugs/ Drugs |
Infections |
Influenza |
2PhII |
ANTI-INFLUENZA A Therapeutic area:
Infections
|
 |
Roche |
CRENEZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
CRENEZUMAB Therapeutic area:
Central Nervous System
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Metastases |
2PhII |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
TAMIFLU |
Biodrugs/ Drugs |
Infections |
Influenza |
1PhI |
TAMIFLU Therapeutic area:
Infections
|
 |
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IMGATUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
colorectal cancer |
1PhI |
CEA CD3 TCB Therapeutic area:
Cancer
|
 |
Roche |
XOLAIR |
Biodrugs/ Drugs |
Autoimmune & Inflammation Dermatology |
Dermatitis (Allergic Contact) |
3PhIII |
XOLAIR Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
TARCEVA Therapeutic area:
Cancer
|
 |
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
IMGATUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
SERD(3) (9545) |
Biodrugs/ Drugs |
Cancer |
breast cancer metastatic |
1PhI |
SERD(3) (9545) Therapeutic area:
Cancer
|
 |
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA CD3 TCB Therapeutic area:
Cancer
|
 |
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
herceptin Therapeutic area:
Cancer
|
 |
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
PDL1 MAB Therapeutic area:
Cancer
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
GAZYVA Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
2PhII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
OCREVUS |
Biodrugs/ Drugs |
Cancer |
Renal cancer carncinoma |
3PhIII |
OCREVUS Therapeutic area:
Cancer
|
 |
Roche |
MABTHERA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Other necrotizing vasculopathies |
3PhIII |
MABTHERA Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Roche |
Balovaptan |
Biodrugs/ Drugs |
Central Nervous System |
Autism |
3PhIII |
Balovaptan Therapeutic area:
Central Nervous System
|
 |
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
COBIMETINIB Therapeutic area:
Cancer
|
 |
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
1PhI |
CEA CD3 TCB Therapeutic area:
Cancer
|
 |
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Systemic lupus erythematosus |
3PhIII |
OCRELIZUMAB Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
breast cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of cervix uteri |
2PhII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
DANOPREVIR |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
DANOPREVIR Therapeutic area:
Infections
|
 |
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Plasma cell neoplasm |
2PhII |
COTELLIC Therapeutic area:
Cancer
|
 |
Roche |
TASPOGLUTIDE |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
TASPOGLUTIDE Therapeutic area:
Metabolic / Endocrinology
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
3PhIII |
ACTEMRA Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
plasma cell neoplasm |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of pancreas |
2PhII |
TARCEVA Therapeutic area:
Cancer
|
 |
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
IMGATUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lungs |
4Reg. |
TARCEVA Therapeutic area:
Cancer
|
 |
Roche |
CIF MEK INH |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CIF MEK INH Therapeutic area:
Cancer
|
 |
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
4Reg. |
herceptin Therapeutic area:
Cancer
|
 |
Roche |
CEACAM5 CEA TCB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
CEACAM5 CEA TCB Therapeutic area:
Cancer
|
 |
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
PDL1 MAB Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Head and neck cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
ERIVEDGE Therapeutic area:
Cancer
|
 |
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
DULIGOTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
Esbriet |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiophatic pulmonary fibrosis |
2PhII |
Esbriet Therapeutic area:
Respiratory and Pulmonary system
|
 |
Roche |
VALCYTE |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Transplanted organ and tissue status (Excl. complications) |
3PhIII |
VALCYTE Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
1PhI |
LUMRETUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Peripheral Vascular Diseases |
3PhIII |
ACTEMRA Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
XELODA Therapeutic area:
Cancer
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Breast Cancer |
3PhIII |
TASELISIB Therapeutic area:
Cancer
|
 |
Roche |
EM MS BIOMARKER |
Biodrugs/ Drugs |
Autoimmune & Inflammation Digestive System |
Crohn's disease |
1PhI |
EM MS BIOMARKER Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
1PhI |
IL22 Fc Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
3PhIII |
XELODA Therapeutic area:
Cancer
|
 |
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LUMRETUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
Cergutuzumab amunaleukin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
Cergutuzumab amunaleukin Therapeutic area:
Cancer
|
 |
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ONARTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Hepatocellular carcinoma |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ERIVEDGE Therapeutic area:
Cancer
|
 |
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
DULIGOTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
FENEBRUTINIB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
FENEBRUTINIB Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Thyrotoxicosis (hyperthyroidism) |
3PhIII |
ACTEMRA Therapeutic area:
Metabolic / Endocrinology
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Renal cell carcinoma |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ZELBORAF Therapeutic area:
Cancer
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of prostate |
2PhII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
ALECTINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECTINIB Therapeutic area:
Cancer
|
 |
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's Lymphoma |
2PhII |
Venclexta Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LIFASTUZUMAB VEDOTIN Therapeutic area:
Cancer
|
 |
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
IL22 Fc Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
Idasanutlin |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Leukaemia Acute |
3PhIII |
Idasanutlin Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
3PhIII |
ZELBORAF Therapeutic area:
Cancer
|
 |
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
LUMRETUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
DSTA4637S |
Biodrugs/ Drugs |
Infections |
Bacterial infection of unespecified site |
1PhI |
DSTA4637S Therapeutic area:
Infections
|
 |
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
ONARTUZUMAB Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
kidney cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Autoimmune & Inflammation Cancer |
Other disorders involving the immune mechanism |
2PhII |
ERIVEDGE Therapeutic area:
Autoimmune & Inflammation / Cancer
|
 |
Roche |
EM ACTEMAB RA |
Biodrugs/ Drugs |
Autoimmune & Inflammation Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
EM ACTEMAB RA Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
 |
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
KADCYLA Therapeutic area:
Cancer
|
 |
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
3PhIII |
AVASTIN Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
2PhII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
BITOPERTIN |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
3PhIII |
BITOPERTIN Therapeutic area:
Central Nervous System
|
 |
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Giant Cel arteritis |
3PhIII |
ACTEMRA Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoid leukaemia |
3PhIII |
Venclexta Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
OX40 Therapeutic area:
Cancer
|
 |
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
IPATASERTIB Therapeutic area:
Cancer
|
 |
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PDL1 MAB Therapeutic area:
Cancer
|
 |
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
ulcerative colitis |
3PhIII |
ETROLIZUMAB Therapeutic area:
Autoimmune & Inflammation
|
 |
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
PDL1 MAB Therapeutic area:
Cancer
|
 |
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
Tecentriq Therapeutic area:
Cancer
|
 |
Roche |
FORTOVASE |
Biodrugs/ Drugs |
Infections |
HIV disease unspecified |
2PhII |
FORTOVASE Therapeutic area:
Infections
|
 |
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems Cancer |
Lymphoid leukaemia |
2PhII |
GAZYVA Therapeutic area:
Blood and Lymphatic systems / Cancer
|